Trials
Search / Trial NCT06418399

The Role of Central Sensitization in Pain, Functionality, and Quality of Life in Cancer Patients

Launched by MARMARA UNIVERSITY · May 13, 2024

Apply for Trial

Trial Information

Current as of March 13, 2025

Not yet recruiting

Keywords

Central Sensitization Cancer Patients

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • Aged between 18 and 80 years
  • • 1. Diagnosis of cancer confirmed pathologically
  • • 2. Experiencing cancer or cancer treatment-related pain complaints for more than 3 months
  • Exclusion Criteria:
  • • 1.Patients with chronic pain not related to cancer will be excluded from the study 2.Patients who do not provide consent to participate in the study 3.Patients with conditions such as dementia, traumatic brain injury, advanced psychiatric disorders (schizophrenia, etc.), chromosomal disorders (Down syndrome), genetic diseases (fragile X syndrome), and neurodegenerative diseases that may lead to mental disorders.

Trial Officials

Savaş Şencan, Assoc. Prof.

Study Director

Marmara University Faculty of Medicine, Department of Pain Medicine

Serdar Kokar, Assoc. Prof.

Study Director

Marmara University Faculty of Medicine, Department of Pain Medicine

About Marmara University

Marmara University is a distinguished academic institution located in Istanbul, Turkey, renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a robust infrastructure and a multidisciplinary approach, the university actively engages in the development and evaluation of new therapeutic interventions, fostering collaboration among researchers, clinicians, and industry partners. Marmara University’s focus on ethical standards and patient safety underscores its dedication to contributing valuable insights to the medical community and improving health outcomes.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0